Table 4.
Tight junction protein | Control (n = 50) | PDS (n = 26) | EPS (n = 27) | Mixed (n = 45) | P-value (FD subtypes) |
---|---|---|---|---|---|
CLDN1 | 0.8 (0.5-1.5) | 1.3 (1.0-1.5) | 1.0 (0.7-1.5) | 0.7 (0.5-1.5) | 0.079 |
Male | 0.8 (0.4-3.4) | 2.3 (1.0-3.9) | 1.4 (0.9-2.2) | 1.2 (0.7-2.8) | 0.631 |
Female | 0.8 (0.5-1.3) | 1.2 (1.0-1.4) | 0.8 (0.7-1.0) | 0.7 (0.5-1.0) | 0.087 |
P-value (male vs female) | 0.513 | 0.259 | 0.284 | 0.076 | |
CLDN2 | 0.9 (0.5-1.1) | 1.6 (1.0-2.6)a | 1.6 (0.8-2.3)a | 1.3 (0.5-2.1) | 0.029 |
Male | 0.6 (0.2-1.0) | 1.1 (0.8-1.6) | 1.5 (0.9-1.9) | 1.4 (0.7-2.2) | 0.050 |
Female | 1.1 (0.6-1.5) | 2.4 (1.5-3.2) | 1.7 (0.7-3.2) | 1.1 (0.4-2.0) | 0.209 |
P-value (male vs female) | 0.037 | 0.106 | 0.622 | 0.621 | |
CLDN4 | 1.1 (0.3-1.6) | 1.5 (1.0-1.8) | 1.6 (1.3-2.0) | 1.4 (0.7-1.8) | 0.238 |
Male | 1.1 (0.2-2.3) | 1.4 (0.7-1.8) | 1.6 (1.4-2.0) | 1.7 (1.2-1.9) | 0.730 |
Female | 1.3 (0.4-1.5) | 1.5 (1.1-1.8) | 1.6 (0.9-2.3) | 1.3 (0.6-1.8) | 0.306 |
P-value (male vs female) | 0.713 | 0.805 | 1.000 | 0.302 | |
OCLN | 0.8 (0.5-1.7) | 1.5 (0.5-3.7) | 1.3 (0.6-2.6) | 1.0 (0.6-1.3) | 0.608 |
Male | 0.8 (0.5-1.2) | 1.9 (0.7-5.7) | 2.0 (1.0-3.3) | 1.1 (0.6-2.7) | 0.261 |
Female | 1.1 (0.5-2.4) | 1.1 (0.4-3.4) | 1.0 (0.5-2.0) | 1.0 (0.5-1.1) | 0.871 |
P-value (male vs female) | 0.649 | 0.639 | 0.214 | 0.443 | |
ZO-1 | 4.1 (0.4-10.9) | 0.5 (0.1-10.6) | 0.6 (0.1-1.2) | 1.7 (0.5-6.0) | 0.092 |
Male | 7.4 (1.4-13.8) | 4.9 (0.4-14.3) | 1.4 (1.1-6.1) | 1.9 (0.5-5.0) | 0.691 |
Female | 1.5 (0.3-7.6) | 0.2 (0.1-2.0) | 0.4 (0.1-0.8) | 1.2 (0.7-5.4) | 0.063 |
P-value (male vs female) | 0.648 | 0.310 | 0.024 | 0.953 |
Statistically significant compared to control group.
PDS, postprandial distress syndrome; EPS, epigastric pain syndrome; FD, functional dyspepsia; CLDN, claudin; OCLN, occludin; ZO-1, zonula occludens-1.
Data are presented as median (interquartile range).